CDM1102

CMD1102 is a novel formulation of a naturally occurring peptide that increases beta cell mass within the islet structure. This novel formulation will enable oral delivery and optimize efficacy of this peptide and provide for physiologic dosing that matches most closely the normal action of this peptide.

Key features include:

• Oral absorption and elimination of injections provides better compliance with physiologic dosing
• Oral delivery provides more physiologic dosing and ability to employ as a short-lived peptide instead of trying to modify it to extend its lifetime and bioavailability